AXID
LOE ApproachingNDAORALCAPSULE
Approved
Apr 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AXID is an oral small-molecule capsule approved in 1988 by GSK for an undisclosed indication. The mechanism of action and specific therapeutic area are not documented in available data, limiting characterization of its clinical role and patient population.
LOE Approaching
Product is in late-stage lifecycle with minimal linked job openings and limited commercial expansion potential.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery
Started Oct 2018
Systane Ultra Versus Maxidex Versus Saline
Started May 2012
36 enrolled
Dry Eye Disease
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
Started Mar 2010
180 enrolled
Allergic Conjunctivitis
Career Relevance
AXID offers minimal active career opportunities, with zero linked job openings reflecting its LOE-approaching status. Roles tied to this product focus on defending market share, managing generic transition, and optimizing profitability rather than growth.
Worked on AXID at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.